αvβ3 and αvβ5 Integrin Expression in Glioma Periphery

Bello, Lorenzo; Francolini, Maura; Marthyn, Paola; Zhang, Jianping; Carroll, Rona S.; Nikas, Demetrios C.; Strasser, Jon; Villani, R.; Cheresh, David A.; Black, Peter McL.

doi:10.1097/00006123-200108000-00022

Cited by 195 publications

(159 citation statements)

References 43 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…Otherwise, the radioactivities found in all the other dissected organs were in the same range for both the LNC throughout the studied time scale. There were minor differences in the circulation time of the LNC tested, however the differences were not statistically significant: 46.7±5.3% and 39.8±5.6% at 1 h, 35.0±4.0% and 30.7±3.5% at 3h, and 3.2±0.5% and 3.3±0.1% at 24 for LNC-cRGD and LNC-cRAD, respectively. Radioactivity levels observed in tumours were the following: ID/g values 3.6±1.1%, 3.5±0.4% and 4.0±1.3% (LNC-cRGD) and 1.8±0.4%, 2.1±0.8% and 3.4±0.6% (LNC-cRAD) at 1, 3 and 24 h, respectively.…”

Section: In Vivo Biodistributionmentioning

confidence: 79%

See 1 more Smart Citation

Tumour targeting of lipid nanocapsules grafted with cRGD peptides

Hirsjärvi

Belloche

Hindré

et al. 2014

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Combining targeting to therapy remains a major challenge in cancer treatment. To address this subject, the surface of lipid nanocapsules (LNC) were modified by grafting cRGD peptides, which are known to be recognised by α v β 3 integrins expressed by tumour endothelium and cancer cells. Applicability of this LNC-cRGD in tumour targeting was first assessed in vitro by the use of U87MG glioma cells. Biodistribution and tumour accumulation of radiolabelled LNC-cRGD in vivo were then evaluated in mice bearing the same subcutaneous xenograft. Flow cytometry and confocal microscopy results revealed that the cRGD grafting improved binding and internalization compared to negative control LNCcRAD and blank LNC. The peptide-grafted LNC remained in the blood circulation up to 3 hours with reduced capture by the RES organs. Tumour accumulation of LNC-cRGD with respect to LNC-cRAD was significantly higher at 1-3 hours. These results show that cRGD grafted to LNC has created a promising tumour-targetable nanocarrier that could be used in cancer treatment.

show abstract

Section: In Vivo Biodistributionmentioning

confidence: 79%

“…Glioblastomas are aggressive, highly vascularized brain tumours that display poor patient survival and prognosis with current therapies. These tumours and the associated newly formed vasculature express α v β 3 integrin [35].…”

Section: Introductionmentioning

confidence: 99%

Tumour targeting of lipid nanocapsules grafted with cRGD peptides

Hirsjärvi

Belloche

Hindré

et al. 2014

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…Integrin α v β 3 is expressed on the most aggressive tumor cells in many cancers including high-grade glioma [21], and its expression correlates with metastasis by recruiting c-Src to integrin β 3 [22]. Recent study has revealed that integrin β 3 is necessary and sufficient to account for stemness and drug resistance by activating Ras/RalB/TBK1/NF-κB pathway [23,24].…”

Section: Discussionmentioning

confidence: 99%

Tip60 regulates MT1-MMP transcription and invasion of glioblastoma cells through NF-κB pathway

Takino

Nakada

et al. 2015

Clin Exp Metastasis

View full text Add to dashboard Cite

A histone acetyltransferase Tat-interacting protein 60 kDa (Tip60) regulates the DNA damage response by acetylating histone and remodeling chromatin. In addition to histone acetyltransferase activity, Tip60 is known to regulate a variety of cellular functions, including gene expression, DNA damage response, cell migration and apoptosis. Lower expression of Tip60 is observed in lymphomas, melanomas, breast, colon, and lung cancer. It is widely accepted that Tip60 functions as a tumor suppressor. However, a role of Tip60 in gliomas still remains unclear. In this study, we investigated the role of Tip60 in the malignant behavior of human gliomas. By quantitative RT-PCR analysis using fresh human brain tumor tissues from 55 patients, we found that lower Tip60 expression and higher membrane-type 1 matrix metalloproteinase (MT1-MMP) expression are associated with advanced tumor grade in glioma tissues. Knockdown of Tip60 in glioblastoma cells promoted cell adhesion, spreading and MT1-MMP transcription and thereby invasion, which was suppressed by inhibition of MT1-MMP and nuclear factor-kappa B (NF-κB) activity. We demonstrate for the first time that tumor suppressor Tip60 down-regulates cell adhesion and MT1-MMP expression and thereby invasion of glioblastoma cells by suppressing NF-κB pathway.Abbreviations: ECM, extracellular matrix; HAT, histone acetyltransferase; HDAC, histone deacetylase; MT1-MMP, membrane-type 1 matrix metalloproteinase; NF-κB, nuclear factor-kappa B; PBS, phosphate-buffered saline; QRT-PCR, quantitative real-time-PCR; Tip60, Tat-interacting protein 60 kDa;

show abstract

“…Integrin α v β 3 is a receptor for the extracellular matrix proteins with exposed arginine-glycine-aspartic (RGD) tripeptide sequence [6][7][8][9][10]. Integrin α v β 3 is normally expressed at low levels on epithelial cells and mature endothelial cells; but it is highly expressed on the activated endothelial cells in neovasculature of tumors, including osteosarcomas, glioblastomas, melanomas, lung carcinomas, and breast cancer [5,[11][12][13][14][15][16][17][18]. It has demonstrated that integrin α v β 3 is overexpressed on both endothelial and tumor cells in human breast cancer xenografts [19].…”

Section: Introductionmentioning

confidence: 99%

“…It has demonstrated that integrin α v β 3 is overexpressed on both endothelial and tumor cells in human breast cancer xenografts [19]. It was also reported that the integrin α v β 3 expression correlates well with tumor progression and invasiveness of melanoma, glioma, ovarian and breast cancers [8][9][10][11][12][13][14][15][16][17][18]. The highly restricted expression of integrin α v β 3 during tumor growth, invasion and metastasis present an interesting molecular target for early detection of rapidly growing and metastatic tumors [19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Coligand effects on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramer

Liu

Kim

Hsieh

et al. 2008

Nuclear Medicine and Biology

View full text Add to dashboard Cite

In this study, we present the evaluation of two new ternary ligand 99m Tc complexes [ 99m Tc(HYNICtetramer)(tricine)(L)] (L = ISONIC and PDA) as potential radiotracers for tumor imaging. The athymic nude mice bearing the MDA-MB-435 human breast cancer xenografts were used to evaluate their biodistribution and metabolic properties. The solution stability data showed that [ 99m Tc (HYNIC-tetramer)(tricine)(L)] (L = ISONIC and PDA) had a significant (14% and 35%, respectively) at 6 h in the absence of excess ISONIC or PDA coligand. Biodistribution data clearly showed that [ 99m Tc(HYNIC-tetramer)(tricine)(PDA)] has much lower uptake in most organs of interest than [ 99m Tc(HYNIC-tetramer)(tricine)(ISONIC)] during the 2 h study period. Results from metabolism studies revealed that ~50% of [ 99m Tc(HYNIC-tetramer)(tricine)(ISONIC)] remained intact in feces samples at 120 min p.i. Only 10% of [ 99m Tc(HYNIC-tetramer)(tricine)(PDA)] remained intact in feces samples. The extent of metabolism correlates well with the radiotracer solution stability. The results from this and our previous studies clearly demonstrated that coligands (TPPTS, ISONIC and PDA) have a significant impact on tumor uptake, excretion kinetics and metabolism of the 99m Tc-labeled cyclic RGDfK tetramer. Among the three radiotracers evaluated in this tumor-bearing animal model, [ 99m Tc(HYNIC-tetramer)(tricine)(TPPTS)] remains the best with respect to blood clearance, tumor uptake, target/background ratios.

show abstract

αvβ3 and αvβ5 Integrin Expression in Glioma Periphery

Abstract: Our data support the role of integrins alpha(v)beta3 and alpha(v)beta5 in glioma-associated angiogenesis. In addition, they suggest a role for integrin alpha(v)beta3 in neoangiogenesis and cell migration in high-grade glioma periphery.

Cited by 195 publications

References 43 publications

Tumour targeting of lipid nanocapsules grafted with cRGD peptides

Tumour targeting of lipid nanocapsules grafted with cRGD peptides

Tip60 regulates MT1-MMP transcription and invasion of glioblastoma cells through NF-κB pathway

Coligand effects on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramer

Contact Info

Product

Resources

About